PDE4B

Phosphodiesterase 4B, cAMP-specific

PDB rendering based on 1f0j.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols PDE4B ; DPDE4; PDEIVB
External IDs OMIM: 600127 MGI: 99557 HomoloGene: 1953 ChEMBL: 275 GeneCards: PDE4B Gene
EC number 3.1.4.53
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 5142 18578
Ensembl ENSG00000184588 ENSMUSG00000028525
UniProt Q07343 B1AWC8
RefSeq (mRNA) NM_001037339 NM_001177980
RefSeq (protein) NP_001032416 NP_001171451
Location (UCSC) Chr 1:
65.79 – 66.37 Mb
Chr 4:
102.09 – 102.61 Mb
PubMed search

cAMP-specific 3',5'-cyclic phosphodiesterase 4B is an enzyme that in humans is encoded by the PDE4B gene.[1]

This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.[1][2]

Clinical relevance

Altered activity of this protein has been associated with schizophrenia and bipolar disorder.[1] PDE4B is believed to be the PDE4 subtype involved in the antipsychotic effects of PDE4 inhibitors such as rolipram.[3] PDE4B is involved in dopamine-associated and stress-related behaviours.[4] It has also recently been implicated in Alzheimer's disease.[5]

Inhibitors

AN2728, a boron-containing drug candidate that as of 2015 was under development by Anacor Pharmaceuticals for the topical treatment of psoriasis and atopic dermatitis (atopic eczema).[6][7][8] mainly acting on PDE4B.[8]

References

  1. 1 2 3 "Entrez Gene: PDE4B phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)".
  2. Swerdlow, Neal R. (2010-08-19). Behavioral Neurobiology of Schizophrenia and Its Treatment. Springer Science & Business Media. ISBN 9783642137174.
  3. Porteous DJ, Millar JK, Brandon NJ, Sawa A (Dec 2011). "DISC1 at 10: connecting psychiatric genetics and neuroscience". Trends in Molecular Medicine 17 (12): 699–706. doi:10.1016/j.molmed.2011.09.002. PMC 3253483. PMID 22015021.
  4. Francis, SH; Conti, M; Houslay, MD, eds. (2011). Phosphodiesterases as Drug Targets (PDF). Handbook of Experimental Pharmacology 204. Springer Berlin Heidelberg. doi:10.1007/978-3-642-17969-3. ISBN 978-3-642-17968-6.
  5. http://newsdaily.com/2015/08/scientists-researching-brain-disorders-create-super-clever-mice/
  6. Anacor AN2728 at Anacor website Page accessed May 15, 2015
  7. Nazarian R, Weinberg JM (Nov 2009). "AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis". Current Opinion in Investigational Drugs 10 (11): 1236–42. PMID 19876791.
  8. 1 2 Moustafa F, Feldman SR (May 2014). "A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology". Dermatol Online J. 20 (5): 22608. PMID 24852768.

Further reading

This article is issued from Wikipedia - version of the Saturday, January 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.